AU2018385257B2 - Immunostimulatory oligonucleotides - Google Patents

Immunostimulatory oligonucleotides Download PDF

Info

Publication number
AU2018385257B2
AU2018385257B2 AU2018385257A AU2018385257A AU2018385257B2 AU 2018385257 B2 AU2018385257 B2 AU 2018385257B2 AU 2018385257 A AU2018385257 A AU 2018385257A AU 2018385257 A AU2018385257 A AU 2018385257A AU 2018385257 B2 AU2018385257 B2 AU 2018385257B2
Authority
AU
Australia
Prior art keywords
seq
oligonucleotide
tlr21
sequence
cpg
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2018385257A
Other languages
English (en)
Other versions
AU2018385257A1 (en
Inventor
Thomas Ilg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Elanco Animal Health GmbH
Original Assignee
Elanco Animal Health GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elanco Animal Health GmbH filed Critical Elanco Animal Health GmbH
Publication of AU2018385257A1 publication Critical patent/AU2018385257A1/en
Assigned to ELANCO ANIMAL HEALTH GMBH reassignment ELANCO ANIMAL HEALTH GMBH Amend patent request/document other than specification (104) Assignors: BAYER ANIMAL HEALTH GMBH
Application granted granted Critical
Publication of AU2018385257B2 publication Critical patent/AU2018385257B2/en
Priority to AU2025204678A priority Critical patent/AU2025204678A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J51/00—Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/17—Immunomodulatory nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/334—Modified C
    • C12N2310/3341—5-Methylcytosine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3515—Lipophilic moiety, e.g. cholesterol
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/31—Combination therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2018385257A 2017-12-15 2018-12-07 Immunostimulatory oligonucleotides Active AU2018385257B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2025204678A AU2025204678A1 (en) 2017-12-15 2025-06-20 Immunostimulatory oligonucleotides

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
EP17207746 2017-12-15
EP17207746.3 2017-12-15
EP17207740 2017-12-15
EP17207750 2017-12-15
EP17207750.5 2017-12-15
EP17207740.6 2017-12-15
PCT/EP2018/083958 WO2019115386A1 (en) 2017-12-15 2018-12-07 Immunostimulatory oligonucleotides

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2025204678A Division AU2025204678A1 (en) 2017-12-15 2025-06-20 Immunostimulatory oligonucleotides

Publications (2)

Publication Number Publication Date
AU2018385257A1 AU2018385257A1 (en) 2020-06-18
AU2018385257B2 true AU2018385257B2 (en) 2025-04-10

Family

ID=66818991

Family Applications (5)

Application Number Title Priority Date Filing Date
AU2018385257A Active AU2018385257B2 (en) 2017-12-15 2018-12-07 Immunostimulatory oligonucleotides
AU2018382419A Active AU2018382419B2 (en) 2017-12-15 2018-12-07 Immunostimulatory oligonucleotides
AU2018385256A Active AU2018385256B2 (en) 2017-12-15 2018-12-07 Immunostimulatory compositions
AU2025204678A Pending AU2025204678A1 (en) 2017-12-15 2025-06-20 Immunostimulatory oligonucleotides
AU2025205082A Pending AU2025205082A1 (en) 2017-12-15 2025-07-03 Immunostimulatory oligonucleotides

Family Applications After (4)

Application Number Title Priority Date Filing Date
AU2018382419A Active AU2018382419B2 (en) 2017-12-15 2018-12-07 Immunostimulatory oligonucleotides
AU2018385256A Active AU2018385256B2 (en) 2017-12-15 2018-12-07 Immunostimulatory compositions
AU2025204678A Pending AU2025204678A1 (en) 2017-12-15 2025-06-20 Immunostimulatory oligonucleotides
AU2025205082A Pending AU2025205082A1 (en) 2017-12-15 2025-07-03 Immunostimulatory oligonucleotides

Country Status (22)

Country Link
US (7) US11932857B2 (enExample)
EP (4) EP3701032A1 (enExample)
JP (5) JP7458977B2 (enExample)
KR (4) KR20250048594A (enExample)
CN (5) CN111447949B (enExample)
AU (5) AU2018385257B2 (enExample)
BR (2) BR112020011815A2 (enExample)
CA (3) CA3085661A1 (enExample)
CL (3) CL2020001560A1 (enExample)
CO (3) CO2020007102A2 (enExample)
CR (1) CR20200260A (enExample)
DK (1) DK3700564T3 (enExample)
DO (3) DOP2020000113A (enExample)
IL (3) IL274975A (enExample)
MX (4) MX2020006243A (enExample)
PE (3) PE20200933A1 (enExample)
PH (3) PH12020550904A1 (enExample)
SG (3) SG11202004773SA (enExample)
TW (2) TW201940192A (enExample)
UY (3) UY38014A (enExample)
WO (3) WO2019115402A1 (enExample)
ZA (1) ZA202004317B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3993834A1 (en) 2019-07-05 2022-05-11 Tambo, Inc. Trans-cyclooctene bioorthogonal agents and uses in cancer and immunotherapy
US20230241196A1 (en) * 2020-01-27 2023-08-03 Oregon State University Gonorrhea subunit vaccine
CN113493790A (zh) * 2020-04-01 2021-10-12 南京华普生物技术股份有限公司 具有免疫调节功能的CpG ODN及其应用
EP3892260A1 (en) * 2020-04-10 2021-10-13 Bayer Animal Health GmbH Immunostimulatory compositions based on liposomes with zwiterionic and cationic lipids
EP4295917A3 (en) 2020-08-07 2024-02-28 Tambo, Inc. Trans-cyclooctene bioorthogonal agents and uses in cancer and immunotherapy
CN112159814B (zh) * 2020-10-29 2023-05-16 中国农业科学院兰州兽医研究所 一种CpG寡聚脱氧核苷酸及制备与其用途
CN113797329A (zh) * 2021-10-19 2021-12-17 启锰生物科技(江苏)有限公司 一种二价锰佐剂和CpG佐剂的疫苗佐剂组合物及其制作方法
CN116218852A (zh) * 2023-02-22 2023-06-06 中国人民解放军陆军军医大学 一种靶向基因启动子G-四联体区域的sgRNA及其用途
WO2025149000A1 (zh) * 2024-01-09 2025-07-17 康希诺(上海)生物研发有限公司 一种免疫刺激序列截断多聚a尾的序列构建及其应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080050731A1 (en) * 2006-02-10 2008-02-28 Invitrogen Corporation Labeling and detection of nucleic acids

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5719028A (en) * 1992-12-07 1998-02-17 Third Wave Technologies Inc. Cleavase fragment length polymorphism
JP3468773B2 (ja) * 1994-07-15 2003-11-17 ザ ユニバーシティ オブ アイオワ リサーチ ファウンデーション 免疫調節オリゴヌクレオチド
US6693086B1 (en) 1998-06-25 2004-02-17 National Jewish Medical And Research Center Systemic immune activation method using nucleic acid-lipid complexes
SK287400B6 (sk) * 1999-09-25 2010-08-09 University Of Iowa Research Foundation Prostriedok s obsahom imunostimulačnej nukleovej kyseliny a jeho použitie na stimuláciu imunitnej reakcie
AU783118B2 (en) * 1999-09-27 2005-09-29 Coley Pharmaceutical Gmbh Methods related to immunostimulatory nucleic acid-induced interferon
KR100359753B1 (ko) * 1999-12-21 2002-11-09 주식회사 제넥신 면역조절능력 및 안전성이 증가되고 ｄＧ 연속서열이결합된 포스포다이에스터 ＣｐＧ올리고데옥시뉴클레오티드 변형체
JP2004501666A (ja) 2000-06-30 2004-01-22 エピゲノミクス　アーゲー 薬理ゲノミクスのメチル化状態分析のための方法及び核酸
AR040996A1 (es) * 2002-08-19 2005-04-27 Coley Pharm Group Inc Acidos nucleicos inmunoestimuladores
EP1631576A4 (en) * 2003-06-11 2010-08-25 Idera Pharmaceuticals Inc STABILIZED IMMUNOMODULATION OLIGONUCLEOTIDES
CA2536139A1 (en) 2003-09-25 2005-04-07 Coley Pharmaceutical Group, Inc. Nucleic acid-lipophilic conjugates
NZ546475A (en) * 2003-10-30 2008-08-29 Coley Pharm Gmbh C-Class oligonucleotide analogs with enhanced immunostimulatory potency
AU2004291277A1 (en) * 2003-11-05 2005-06-02 Intercell Ag Compositions comprising melittin-derved peptides and methods for the potentiation of immune responses against target antigens
CN1250737C (zh) * 2003-11-07 2006-04-12 深圳市未来海洋科技发展有限公司 含CpG DNA畜禽疫苗佐剂的PCR制备方法
KR100558851B1 (ko) * 2004-01-08 2006-03-10 학교법인연세대학교 면역조절능력이 증가된 ＣｐＧ 올리고데옥시뉴클레오티드변형체
EP1751612B1 (en) * 2004-05-06 2009-02-25 The Government of the United States of America, as represented by the Secretary of the Department of Health and Human Services Methods and compositions for the treatment of uveitis
CN101160401A (zh) * 2005-02-24 2008-04-09 科勒制药集团公司 免疫刺激寡核苷酸
EP1764108A1 (en) * 2005-09-14 2007-03-21 Gunther Hartmann Compositions comprising immunostimulatory RNA oligonucleotides and methods for producing said RNA oligonucleotides
JP5473336B2 (ja) 2006-02-15 2014-04-16 アディウタイド・ファーマスーティカルズ・ゲーエムベーハー オリゴヌクレオチドの処方に関する組成物および方法
CN100418583C (zh) * 2006-02-21 2008-09-17 朱鸿飞 预防和治疗乳腺炎的药物组合物
US20080124366A1 (en) 2006-08-06 2008-05-29 Ohlfest John R Methods and Compositions for Treating Tumors
CN101240271B (zh) * 2006-08-28 2012-08-29 长春华普生物技术有限公司 Toll样受体调节性寡核苷酸及其用途
MX2009003398A (es) 2006-09-27 2009-08-12 Coley Pharm Gmbh Analogos de oligonucleotidos cpg que contienen analogos t hidrofobos con actividad inmunoestimuladora mejorada.
JP4847609B2 (ja) * 2007-08-13 2011-12-28 コーリー ファーマシューティカル ゲーエムベーハー 特異的な免疫修飾プロフィールを誘発する規定されたヌクレオチド間結合との関連におけるｒｎａ配列モチーフ
WO2010129672A1 (en) 2009-05-05 2010-11-11 Miragen Therapeutics Lipophilic polynucleotide conjugates
DK2429581T3 (en) 2009-05-14 2015-11-09 Bayer Ip Gmbh Improved immune responses in birds
CA2800158C (en) 2010-05-28 2020-07-21 Coley Pharmaceutical Group, Inc. Vaccines comprising cholesterol and cpg as sole adjuvant-carrier molecules
CN101979542B (zh) * 2010-10-28 2011-12-28 国家兽用生物制品工程技术研究中心 含CpG基序的核酸序列的制备方法及应用
PT2654785T (pt) * 2010-12-22 2019-06-25 Bayer Ip Gmbh Resposta imunitária melhorada em espécies bovinas
EP2471926A3 (en) * 2010-12-30 2012-07-11 Intervet International BV Immunostimulatory oligodeoxynucleotides
BR112013029968A2 (pt) * 2011-05-26 2017-01-31 Intervet Int Bv oligodesoxinucleotídeo imunoestimulatório não metilado, vetor, vacina para prevenir ou combater uma doença infecciosa, e, método para a detecção de oligodesoxinucleotídeos imunoestimulatórios
MX2013013801A (es) * 2011-05-26 2013-12-16 Intervet Int Bv Oligodesoxinucleotidos inmunoestimuladores.
WO2013151771A1 (en) 2012-04-05 2013-10-10 Massachusetts Institute Of Technology Immunostimulatory compositions and methods of use thereof
AR091569A1 (es) 2012-06-28 2015-02-11 Intervet Int Bv Receptores de tipo toll
US20150301058A1 (en) * 2012-11-26 2015-10-22 Caris Science, Inc. Biomarker compositions and methods
US9506030B2 (en) 2013-05-01 2016-11-29 Regulus Therapeutics Inc. Compounds and methods for enhanced cellular uptake
WO2015010070A1 (en) * 2013-07-19 2015-01-22 National Health Research Institutes Cpg-oligodeoxynucleotide, immunogenic composition comprising the same, and methods for preparing the composition and stimulating immune response thereby
AR097029A1 (es) * 2013-07-26 2016-02-17 Intervet Int Bv Aceleración de la respuesta inmune inducida por virus vectorial en aves, composición, uso, método para la vacunación y método para acelerar la respuesta inmune
GB2517700A (en) * 2013-08-27 2015-03-04 Lgc Ltd Oligonucleotides comprising a secondary structure and uses thereof
MX2016010993A (es) 2014-02-28 2017-05-01 Bayer Animal Health Gmbh Plasmidos inmunoestimuladores.
WO2017139570A1 (en) * 2016-02-12 2017-08-17 Massachusetts Intitute Of Technology Synergistic tumor treatment with il-2, an integrin-binding-fc fusion protein, and a cancer vaccinne

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080050731A1 (en) * 2006-02-10 2008-02-28 Invitrogen Corporation Labeling and detection of nucleic acids

Also Published As

Publication number Publication date
AU2018385256B2 (en) 2025-09-25
CA3085657A1 (en) 2019-06-20
RU2020122553A (ru) 2022-01-17
JP2023156485A (ja) 2023-10-24
CN111447949B (zh) 2025-07-11
PH12020550903A1 (en) 2021-05-17
BR112020011838A2 (pt) 2020-11-24
PE20210636A1 (es) 2021-03-23
US20230332162A1 (en) 2023-10-19
SG11202004773SA (en) 2020-06-29
US20230174990A1 (en) 2023-06-08
KR20200098638A (ko) 2020-08-20
TW201936924A (zh) 2019-09-16
EP3694549A1 (en) 2020-08-19
JP7760560B2 (ja) 2025-10-27
DOP2020000106A (es) 2020-08-31
CR20200260A (es) 2020-08-01
CN119656298A (zh) 2025-03-21
DK3700564T3 (da) 2025-11-10
SG11202004952UA (en) 2020-06-29
AU2018382419B2 (en) 2025-04-10
CL2020001562A1 (es) 2020-11-06
JP2021506246A (ja) 2021-02-22
BR112020011815A2 (pt) 2020-11-17
WO2019115386A1 (en) 2019-06-20
CA3085661A1 (en) 2019-06-20
TW201936923A (zh) 2019-09-16
JP7770769B2 (ja) 2025-11-17
JP7273040B2 (ja) 2023-05-12
AU2025204678A1 (en) 2025-07-17
EP3700564A1 (en) 2020-09-02
US11932857B2 (en) 2024-03-19
CN111801116B (zh) 2024-11-26
US20210062192A1 (en) 2021-03-04
CN111447949A (zh) 2020-07-24
AU2018385257A1 (en) 2020-06-18
EP3701032A1 (en) 2020-09-02
RU2020122545A3 (enExample) 2022-05-04
US20210170020A1 (en) 2021-06-10
WO2019115402A1 (en) 2019-06-20
TW201940192A (zh) 2019-10-16
US12305173B2 (en) 2025-05-20
CN120519464A (zh) 2025-08-22
CN111801116A (zh) 2020-10-20
MX2025007909A (es) 2025-08-01
CO2020007120A2 (es) 2020-06-19
US11542507B2 (en) 2023-01-03
KR20200099556A (ko) 2020-08-24
DOP2020000113A (es) 2020-08-31
MX2020006244A (es) 2020-09-03
CL2020001561A1 (es) 2020-11-06
JP2021506779A (ja) 2021-02-22
ZA202004317B (en) 2023-05-31
JP2023153970A (ja) 2023-10-18
CL2020001560A1 (es) 2020-11-06
KR102787688B1 (ko) 2025-03-27
IL275086A (en) 2020-07-30
UY38015A (es) 2019-06-28
PH12020550906A1 (en) 2021-05-17
AU2025205082A1 (en) 2025-07-31
US20250215439A1 (en) 2025-07-03
US20200385733A1 (en) 2020-12-10
WO2019115385A1 (en) 2019-06-20
WO2019115386A9 (en) 2020-07-23
MX2020006243A (es) 2020-09-03
JP2021506245A (ja) 2021-02-22
UY38014A (es) 2019-06-28
SG11202004471RA (en) 2020-06-29
AU2018382419A1 (en) 2020-06-04
PH12020550904A1 (en) 2021-05-17
CA3085575A1 (en) 2019-06-20
RU2020122545A (ru) 2022-01-19
CO2020007102A2 (es) 2020-06-19
DOP2020000107A (es) 2020-08-31
EP4647437A2 (en) 2025-11-12
KR20250048594A (ko) 2025-04-09
MX2020006246A (es) 2020-09-03
AU2018385256A1 (en) 2020-06-11
CN111801419A (zh) 2020-10-20
CO2020007100A2 (es) 2020-06-19
BR112020011845A2 (pt) 2020-11-24
IL275217A (en) 2020-07-30
US20240076681A1 (en) 2024-03-07
PE20200933A1 (es) 2020-09-17
PE20210635A1 (es) 2021-03-23
TWI821224B (zh) 2023-11-11
UY38016A (es) 2019-06-28
JP7458977B2 (ja) 2024-04-01
KR20200098637A (ko) 2020-08-20
IL274975A (en) 2020-07-30
EP3700564B1 (en) 2025-09-17

Similar Documents

Publication Publication Date Title
AU2018385257B2 (en) Immunostimulatory oligonucleotides
RU2615457C2 (ru) Иммуностимулирующие олигодезоксинуклеотиды
AU2020337918A1 (en) Modified circular RNAs and methods of use thereof
EP2714907B1 (en) Immunostimulatory oligodeoxynucleotides
CN103547675A (zh) 免疫刺激性寡脱氧核苷酸
JP2003502345A (ja) ペットまたはスポ−ツ用動物のためのｄｎａワクチン
KR20220044395A (ko) 구제역 백신
JP6427487B2 (ja) Ｔｏｌｌ様受容体
EP3024935A1 (en) Acceleration of vector virus induced immune response in avians
RU2795701C2 (ru) Иммуностимулирующие олигонуклеотиды
TWI900461B (zh) 免疫刺激性寡核苷酸
HK40039984A (en) Immunostimulatory oligonucleotides
HK40039985A (en) Immunostimulatory compositions
BR112020011845B1 (pt) Composições imunoestimulatórias e método de preparação das mesmas
CN118910110A (zh) 一种CpG佐剂及其应用

Legal Events

Date Code Title Description
HB Alteration of name in register

Owner name: ELANCO ANIMAL HEALTH GMBH

Free format text: FORMER NAME(S): BAYER ANIMAL HEALTH GMBH

FGA Letters patent sealed or granted (standard patent)